S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide}
Ovarian Cancer
Explore 513 assets in Ovarian Cancer →Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
BicycleTx Limited
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04180371CT.gov Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide} (this asset) | BicycleTx Limited | P1/2 | CC · 40 |
| Olaparib | Shandong University | P4 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
| Adriamycin | Genmab | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Nogitecan | Genmab | P3 | BB |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide}
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Carcinoma | — | P1/2 | CCC · 48 |
| Gastric Cancer | — | P1/2 | CCC · 48 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide} in Ovarian Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/ssup315supssup322supssup329sup-135-triazinane-135-triyltris3-oxopropane-31-diyln-5-oxo-5-l-valyl-nsup5sup-carbamoyl-l-ornithyl4-aminophenylmethoxycarbonyl-n-methyl-l-valyl-lvalyl-3r4s5s-3-methoxy-5-methyl-4-methylaminoheptanoyl-2r3r-n-1s2r-1-hydroxy-1-phenylpropan-2-yl-3-methoxy-2-methyl-3-2s-pyrrolidin-2-ylpropanamide-n21-ylpentanoyl-alanyldecakisn-methylglycyl-l-alanyl-n6-carbamimidoyl-l-lysyl-l-aspartyl-l-cysteinyl-4r-4-hydroxy-l-prolyl-l-leucyl-l-valyl-l-asparaginyl-l-prolyl-l-leucyl-l-cysteinyl-l-leucyl-l-histidyl-l-prolyl-d-aspartyl-l-tryptophyl-n6-carbamimidoyl-l-lysyl-lcysteinamide-ovarian-cancerAre you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →